SanBio Company Limited

Tokyo Stock Exchange 4592.T

SanBio Company Limited EBITDA Margin for the year ending January 31, 2024

SanBio Company Limited EBITDA Margin is NA for the year ending January 31, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

SanBio Company Limited EBITDA Margin for the year ending January 31, 2020 was -1,131.43%, a -200.83% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Tokyo Stock Exchange: 4592.T

SanBio Company Limited

CEO	Mr. Keita Mori MBA
IPO Date	April 8, 2015
Location	Japan
Headquarters	St. Luke Tower
Employees	29
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals Robotics

Description

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years